What is the company's overall financial performance for the quarter?

For the quarter ended June 30, 2007, Edwards Lifesciences reported net sales of $272.6 million, a slight increase of 2.0% year-over-year. However, net income decreased to $34.9 million from $36.1 million in the prior year's comparable quarter. Diluted earnings per share also saw a slight decrease to $0.57 from $0.58.

Which product segments are driving sales growth, and which are declining?

The Heart Valve Therapy and Critical Care segments are the primary drivers of sales growth. Heart Valve Therapy sales increased 2.7% driven by premium valve products, while Critical Care sales grew by 8.7%, notably boosted by the FloTrac system. Cardiac Surgery Systems experienced a significant decline of 37.4%, primarily due to the divestiture of product lines and exiting the TMR market.

What is the significance of the $150 million in convertible debt being reclassified as a current liability?

The $150 million in convertible senior debentures were reclassified from long-term to current liabilities because holders have the right to require the company to purchase them for cash on May 15, 2008. This means the company needs to have the funds available to repay or refinance this debt within the next year.

How are the company's investments in new technologies, such as transcatheter valves, impacting its financials?

The company is significantly increasing its R&D spending, particularly on transcatheter valve development programs like the SAPIEN THV technology. While this investment is crucial for future growth and has led to new clinical trials and product development, it also contributes to higher R&D expenses and impacts short-term profitability.

EW 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported its financial results for the quarter ended June 30, 2007. The company demonstrated modest top-line growth with net sales increasing by 2.0% to $272.6 million for the quarter, and 2.4% to $536.7 million for the six months. This growth was primarily driven by the Heart Valve Therapy and Critical Care segments, with notable contributions from new product launches and international sales, partly aided by favorable foreign currency movements. Profitability showed a slight decline in net income for the quarter, down to $34.9 million ($0.57 diluted EPS) from $36.1 million ($0.58 diluted EPS) in the prior year, and for the six months, down to $68.1 million ($1.11 diluted EPS) from $82.0 million ($1.30 diluted EPS). This was impacted by increased Selling, General & Administrative (SG&A) expenses and higher Research & Development spending, particularly in transcatheter valve development. The company also faced a shift in the competitive landscape and the divestiture of certain product lines impacting revenue comparisons. Financially, the company maintained a solid balance sheet, though current liabilities increased significantly due to the reclassification of convertible debt as a current liability, reflecting its potential redemption in May 2008. Cash flow from operations decreased compared to the prior year, partly due to a significant cash receipt in the prior year from a patent settlement. The company continues to invest in growth initiatives, particularly in its transcatheter valve programs, and has adequate liquidity to fund its operations.

Key Highlights

1Net sales for the quarter ended June 30, 2007, increased 2.0% to $272.6 million, compared to $267.3 million in the prior year.
2Net income for the quarter decreased to $34.9 million ($0.57 diluted EPS) from $36.1 million ($0.58 diluted EPS) in the same period last year.
3The Heart Valve Therapy segment saw a 2.7% increase in net sales, driven by premium valves like the Carpentier-Edwards PERIMOUNT Magna and Magna with ThermaFix.
4Critical Care products experienced a strong 8.7% sales increase, largely attributed to the FloTrac system and pressure monitoring products.
5Research and Development expenses increased due to investments in transcatheter valve development programs, including the SAPIEN Transcatheter Heart Valve (THV).
6Convertible debt of $150.0 million was reclassified as a current liability due to its potential redemption date in May 2008.
7Cash flow from operating activities for the six months ended June 30, 2007, decreased to $73.9 million from $100.6 million in the prior year, impacted by prior year patent settlement cash receipts.

Edwards Lifesciences Corp Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions